Table 4.
Comparison of our findings with those of other studies
| Reference | Technique | n | Median F/U (M) | Dose (Gy or Gy [RBE]) | ADT rate (%) | Biochemical control (%) | Late complications (%) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year | L | I | H+VH | Year | ≥G2 GI | ≥G2 GU | ||||||
| Dearnaley 2007 4 | 3D‐CRT | 421 | 63 | 64 | 100 | 5 | 79 | 70 | 43 | 5 | 24 | 8.0 |
| 422 | 64 | 74 | 100 | 5 | 85 | 79 | 57 | 5 | 33 | 11 | ||
| Kuban 2008 5 | 3D‐CRT | 151 | 104 | 70 | 0 | 8 | 63 | 76 | 26 | 10 | 13 | 8.0 |
| 150 | 104 | 78 | 0 | 8 | 88 | 86 | 63 | 10 | 26 | 13 | ||
| Martin 2009 15 | 3D‐CRT | 259 | 68 | 79.8 | 14/11/46 | 5 | 88 | 77 | 78 | NR | 4.3 | 8.6 |
| Zelefsky 2006 6 | IMRT | 561 | 84 | 81 | 34/52/92 | 8 | 85 | 76 | 72 | 8 | 1.7 | 12 |
| Kupelian 2007 7 | IMRT | 770 | 45 | 70 | 60 | 5 | 94 | 83 | 72 | 5 | 7.0 | 7.0 |
| Cahlon 2008 8 | IMRT | 478 | 53 | 86.4 | 66 | 5 | 98 | 85 | 70 | 5 | 3.4 | 16 |
| Spratt 2013 9 | IMRT | 1001 | 66 | 86.4 | 28/48/91 | 7 | 99 | 86 | 68 | 7 | 4.4 | 21 |
| Zietman 2010 16 | X + Proton | 197 | 66 | 70.2 | 0 | 5 | 60 | 63 | — | NR | 8.0 | 18 |
| 195 | 66 | 79.2 | 0 | 5 | 81 | 80 | — | NR | 17 | 20 | ||
| Johansson 2012 17 | X + Proton | 278 | 57 | 70 | 22/45/76 | 5 | 100 | 95 | 74 | 5 | 10 | 9.0 |
| Ishikawa 2012 18 | Carbon | 927 | 43 | 57.6–66 | 0/100/100 | 5 | 90 | 97 | 88 | 5 | 1.9 | 6.3 |
| Mendenhall 2014 19 | Proton | 211 | 62 | 78–82 | 11/9/100 | 5 | 99 | 99 | 76 | 5 | (1.0)1 | (0.5)1 |
| Bryant 2016 20 | Proton | 1327 | 66 | 78 | 7/10/66 | 5 | 99 | 94 | 74 | 5 | (0.6)1 | (2.9)1 |
| Present study 2016 | Proton | 1375 | 70 | 74–78 | 25/44/87 | 5 | 99 | 91 | 83 | 5 | 3.9 | 2.0 |
3D‐CRT, three‐dimensional conformal radiotherapy; IMRT, intensity‐modulated radiation therapy; X + Proton, combination of X‐ray‐based radiotherapy and proton therapy; Carbon, carbon ion therapy; Proton, proton therapy; F/U, follow‐up; Fr, fractionations; ADT, androgen deprivation therapy; L, low‐risk group; I, intermediate‐risk group; H+VH, high‐risk group, and very high‐risk group; ≥G2 GI, grade 2 or higher late gastrointestinal toxicities; ≥ G2 GU, grade 2 or higher late genitourinary toxicities; NR, not reported. 1Grade 3 or higher late toxicities.